BCL2 and Thrombocytopenia: However, it has been also reported that the first selective and highly potent Bcl-2 inhibitor, venetoclax (formerly ABT-199/GDC-0199), induced significantly less thrombocytopenia than navitoclax [44], although this BH3 mimetic showed significant toxicities on normal human B cells as their malignant counterpart [80].